Literature DB >> 31152129

LSD1 destabilizes FBXW7 and abrogates FBXW7 functions independent of its demethylase activity.

Huiyin Lan1,2, Mingjia Tan2, Qiang Zhang2, Fei Yang1, Siyuan Wang1, Hua Li2, Xiufang Xiong1, Yi Sun3,2.   

Abstract

FBXW7 acts as a typical tumor suppressor, with loss-of-function alterations in human cancers, by promoting ubiquitylation and degradation of many oncoproteins. Lysine-specific demethylase 1 (LSD1) is a well-characterized histone demethylase. Whether LSD1 has demethylase-independent activity remains elusive. Here we report that LSD1 directly binds to FBXW7 to destabilize FBXW7 independent of its demethylase activity. Specifically, LSD1 is a pseudosubstrate of FBXW7 and LSD1-FBXW7 binding does not trigger LSD1 ubiquitylation, but instead promotes FBXW7 self-ubiquitylation by preventing FBXW7 dimerization. The self-ubiquitylated FBXW7 is subjected to degradation by proteasome as well as lysosome in a manner dependent on autophagy protein p62/SQSTM1. Biologically, LSD1 destabilizes FBXW7 to abrogate its functions in growth suppression, nonhomologous end-joining repair, and radioprotection. Collectively, our study revealed a previously unknown activity of LSD1, which likely contributes to its oncogenic function. Targeting LSD1 protein, not only its demethylase activity, might be a unique approach for LSD1-based drug discovery for anticancer application.

Entities:  

Keywords:  DNA damage repair; SCF E3 ligase; degradation; ubiquitylation

Year:  2019        PMID: 31152129      PMCID: PMC6589684          DOI: 10.1073/pnas.1902012116

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication.

Authors:  P Nash; X Tang; S Orlicky; Q Chen; F B Gertler; M D Mendenhall; F Sicheri; T Pawson; M Tyers
Journal:  Nature       Date:  2001-11-29       Impact factor: 49.962

Review 2.  Ubiquitin ligases: cell-cycle control and cancer.

Authors:  Keiichi I Nakayama; Keiko Nakayama
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

3.  The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.

Authors:  Wenyi Wei; Jianping Jin; Susanne Schlisio; J Wade Harper; William G Kaelin
Journal:  Cancer Cell       Date:  2005-07       Impact factor: 31.743

4.  Homodimer of two F-box proteins betaTrCP1 or betaTrCP2 binds to IkappaBalpha for signal-dependent ubiquitination.

Authors:  H Suzuki; T Chiba; T Suzuki; T Fujita; T Ikenoue; M Omata; K Furuichi; H Shikama; K Tanaka
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

5.  The role of autophagy during the early neonatal starvation period.

Authors:  Akiko Kuma; Masahiko Hatano; Makoto Matsui; Akitsugu Yamamoto; Haruaki Nakaya; Tamotsu Yoshimori; Yoshinori Ohsumi; Takeshi Tokuhisa; Noboru Mizushima
Journal:  Nature       Date:  2004-11-03       Impact factor: 49.962

6.  Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.

Authors:  Yujiang Shi; Fei Lan; Caitlin Matson; Peter Mulligan; Johnathan R Whetstine; Philip A Cole; Robert A Casero; Yang Shi
Journal:  Cell       Date:  2004-12-29       Impact factor: 41.582

7.  An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation.

Authors:  Min Gyu Lee; Christopher Wynder; Neil Cooch; Ramin Shiekhattar
Journal:  Nature       Date:  2005-08-03       Impact factor: 49.962

8.  Inactivation of hCDC4 can cause chromosomal instability.

Authors:  Harith Rajagopalan; Prasad V Jallepalli; Carlo Rago; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer
Journal:  Nature       Date:  2004-03-04       Impact factor: 49.962

9.  The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.

Authors:  Markus Welcker; Amir Orian; Jianping Jin; Jonathan E Grim; Jonathan A Grim; J Wade Harper; Robert N Eisenman; Bruce E Clurman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-18       Impact factor: 11.205

10.  Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover.

Authors:  Christy J Fryer; J Brandon White; Katherine A Jones
Journal:  Mol Cell       Date:  2004-11-19       Impact factor: 17.970

View more
  20 in total

1.  FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.

Authors:  Rizwan Saffie; Nan Zhou; Delphine Rolland; Özlem Önder; Venkatesha Basrur; Sydney Campbell; Kathryn E Wellen; Kojo S J Elenitoba-Johnson; Brian C Capell; Luca Busino
Journal:  Cancer Res       Date:  2020-04-29       Impact factor: 12.701

2.  JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL.

Authors:  Aissa Benyoucef; Katharina Haigh; Andrew Cuddihy; Jody J Haigh
Journal:  Leukemia       Date:  2022-10-13       Impact factor: 12.883

Review 3.  Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy.

Authors:  Liangliang Xing; Leidi Xu; Yong Zhang; Yinggang Che; Min Wang; Yongxiang Shao; Dan Qiu; Honglian Yu; Feng Zhao; Jian Zhang
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

4.  FBXO9 Mediates the Cancer-Promoting Effects of ZNF143 by Degrading FBXW7 and Facilitates Drug Resistance in Hepatocellular Carcinoma.

Authors:  Zhenyu Wang; Xiaoxia Chen; Lianer Zhou; Xinge Zhao; Chao Ge; Fangyu Zhao; Haiyang Xie; Taoyang Chen; Hua Tian; Hong Li; Jinjun Li
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

5.  Long noncoding RNA HAS2-AS1 accelerates non-small cell lung cancer chemotherapy resistance by targeting LSD1/EphB3 pathway.

Authors:  Peng Sun; Limin Sun; Jia Cui; Lili Liu; Qing He
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

Review 6.  LSD1: a viable therapeutic target in cutaneous squamous cell carcinoma?

Authors:  Shaun Egolf; Brian C Capell
Journal:  Expert Opin Ther Targets       Date:  2020-05-07       Impact factor: 6.902

Review 7.  LSD1/KDM1A inhibitors in clinical trials: advances and prospects.

Authors:  Yuan Fang; Guochao Liao; Bin Yu
Journal:  J Hematol Oncol       Date:  2019-12-04       Impact factor: 17.388

Review 8.  Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.

Authors:  Maaike G J M van Bergen; Bert A van der Reijden
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

9.  LSD1 contributes to programmed oocyte death by regulating the transcription of autophagy adaptor SQSTM1/p62.

Authors:  Meina He; Tuo Zhang; Zijian Zhu; Shaogang Qin; Huarong Wang; Lihua Zhao; Xinran Zhang; Jiayi Hu; Jia Wen; Han Cai; Qiliang Xin; Qirui Guo; Lin Lin; Bo Zhou; Hua Zhang; Guoliang Xia; Chao Wang
Journal:  Aging Cell       Date:  2020-02-19       Impact factor: 9.304

10.  Myeloid FBW7 deficiency disrupts redox homeostasis and aggravates dietary-induced insulin resistance.

Authors:  Cheng Wang; Yuelin Chao; Wenjing Xu; Zhaoyu Liu; Huan Wang; Kai Huang
Journal:  Redox Biol       Date:  2020-08-15       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.